Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (Note: Request metadata listed "Cardiff Oncology, Inc.", but the filing text identifies the registrant as Trovagene, Inc.) on October 25, 2019. The report details the entry into a Material Definitive Agreement for a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to sell securities to accredited investors with the following terms:
- Gross Proceeds: Approximately $5.0 million.
- Price per Unit: $1.814 per Share and associated Warrants.
- Securities Issued:
- 1,301,268 shares of Common Stock.
- 1,455,072 Pre-Funded Warrants (exercise price $0.01).
- 2,756,340 Series G Warrants (exercise price $1.56; 5.5-year term).
- 2,756,340 Series H Warrants (exercise price $1.56; 18-month term).
- Placement Agent Warrants: 206,726 warrants issued to H.C. Wainwright & Co. (exercise price $2.2675; 5.5-year term).
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes and Agreements
The primary material change is the execution of the Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, the Company must file a Form S-3 Registration Statement within 10 calendar days of the Effective Date to cover the resale of the securities. The Company is required to use best efforts to have the statement declared effective within 30 to 60 days, depending on SEC review status. Failure to meet these filing or effectiveness deadlines may result in liquidated damages payable to investors.
Outlook, Risks, and Unusual Items
The transaction is anticipated to close on or about October 29, 2019, subject to customary closing conditions. The issuance of securities was deemed exempt from registration requirements under Section 4(a)(2) and Rule 506 of the Securities Act of 1933. The filing includes a press release (Exhibit 99.1) announcing the offering. No specific forward-looking guidance, risk factors, or unusual items beyond the standard terms of the offering and registration obligations are detailed in this text.
Investor Verification Checklist
- Verify the closing date of the transaction (anticipated October 29, 2019) and confirmation of fund receipt.
- Confirm the filing and effectiveness status of the Form S-3 Registration Statement required within 10 days of the Effective Date.
- Review the full text of the Purchase Agreement (Exhibit 10.1) and Warrant forms (Exhibit 10.2) for specific covenants and dilution impacts.
- Monitor for any liquidated damages triggers related to registration statement delays.